Monoclonal antibodies remain the most commercially successful biologic drug class, generating over $200 billion in annual global revenue. The field is advancing rapidly toward next-generation formats — bispecific antibodies that engage two targets simultaneously, antibody-drug conjugates that deliver cytotoxic payloads to cancer cells with precision, trispecific antibodies, half-life extended antibodies, and Fc-engineered antibodies with enhanced effector function. Regeneron's VelocImmune platform, Amgen's BiTE bispecific platform, and Gilead's ADC expertise represent the leading antibody engineering capabilities among the ten companies.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Monoclonal Antibody Market
• Bispecific Antibody Pipeline
• ADC Commercial Landscape
• Half-Life Extension Technology
• Antibody Discovery Platforms
• Fc Engineering
• Next-Generation Antibody Formats
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Monoclonal Antibody Market
4. Bispecific Antibody Pipeline
5. ADC Commercial Landscape
6. Half-Life Extension Technology
7. Antibody Discovery Platforms
8. Fc Engineering
9. Next-Generation Antibody Formats
10. Competitive Landscape
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. Monoclonal Antibody Market
Table 3. Bispecific Antibody Pipeline
Table 4. ADC Commercial Landscape
Table 5. Half-Life Extension Technology
Table 6. Antibody Discovery Platforms
Table 7. Fc Engineering
Table 8. Next-Generation Antibody Formats
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
